salicylates and Intestinal-Neoplasms

It is well established that Crohn's disease (CD) is associated with an increased risk of small bowel adenocarcinoma (SBA). The data concerning SBA risk factors in CD are scanty. The aim of this study was to identify them.. In 11 French centers affiliated with the GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif), we identified 29 patients with CD and SBA. Eighty-seven CD controls without SBA recruited in a single center were matched to the cases for sex, age, duration, and CD site. A conditional logistic regression, taking into account the matching between cases and controls, was performed.. In univariate analysis, the cases had had significantly less small bowel resection and received prolonged treatment with salicylates (more than 2 yr), less often than the controls (odds ratio, OR [95% confidence interval, CI] 0.07 [0.01-0.32] and 0.29 [0.10-0.82], respectively). In multivariate analysis, both associations remained significant (OR 0.04 [0.01-0.28], P= 0.001; OR 0.16 [0.03-0.79], P= 0.02, respectively).. This study suggests that small bowel resection and prolonged salicylates use may protect against SBA in CD patients.

Topics: Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Child; Crohn Disease; Female; Humans; Intestinal Neoplasms; Intestine, Small; Logistic Models; Male; Middle Aged; Risk Factors; Salicylates